LAG3 and non-small cell lung carcinoma: This finding is relevant as recently demonstrated by Zhou and colleagues (39) as far as LAG-3 upregulation after EGFR-TKI failure in advanced NSCLC, suggesting the rational use of LAG-3 inhibitors in advanced NSCLC patients with EGFR mutation.